

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OW protein - protein search, using sw model

Run on: June 25, 2003, 14:20:41 ; Search time 31.5 Seconds

(without alignments)
444.165 Million cell updates/sec

Title: US-09-622-613b-8

Perfect score: 58.2

Sequence: 1 HQDWLTFQKKHLTNREVDG.....TFCVCENQAPVHFGVCHC 105

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 901470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

```

1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	567	97.4	105	20	AAV28869
2	565	97.1	105	20	AAV28867
3	562	96.6	104	20	AAV28866
4	560	96.2	104	20	AAV28865
5	560	96.2	105	20	AAV28871
6	560	96.2	127	20	AAV28879
7	555	95.4	104	20	AAV28870
8	540	92.8	104	18	AAW06544
9	540	92.8	105	18	AAW35123
10	540	92.8	105	20	AAV39400

11	540	92.8	355	18	AAW35125	R. pipiens recombi
12	540	92.8	358	18	AAW35130	R. pipiens recombi
13	538	92.4	104	18	AAW30301	Recombinant onc pr
14	538	92.4	104	22	AAW31666	Amino acid sequenc
15	538	92.4	112	18	AAW35118	R. pipiens recombi
16	538	92.4	251	18	AAW35134	R. pipiens recombi
17	538	92.4	254	18	AAW35135	R. pipiens recombi
18	538	92.4	355	18	AAW35129	R. pipiens recombi
19	538	92.4	355	18	AAW35133	R. pipiens recombi
20	538	92.4	366	18	AAW35132	R. pipiens recombi
21	538	92.4	379	18	AAW35126	R. pipiens recombi
22	537	92.3	104	18	AAW30302	Recombinant onc pr
23	535	91.9	104	12	AAW12344	Protein with activ
24	535	91.9	104	15	AAW47303	ONCONASE (pharmace
25	535	91.9	104	17	AAW00736	Protein derived fr
26	535	91.9	104	18	AAW06543	Antitumour protein
27	535	91.9	104	18	AAW14065	Onconase (RTM) pro
28	535	91.9	104	20	AAW33322	Frog onconase prot
29	535	91.9	104	20	AAW88233	Rana pipiens RNase
30	535	91.9	104	22	AAW31667	Amino acid sequenc
31	533	91.6	105	18	AAW35116	R. pipiens recombi
32	533	91.6	106	18	AAW35122	R. pipiens recombi
33	533	91.6	107	18	AAW35117	R. pipiens recombi
34	532	91.4	105	18	AAW35115	R. pipiens recombi
35	530	91.1	104	18	AAW18224	Antitumour generic
36	529	90.9	358	18	AAW35127	R. pipiens recombi
37	529	90.9	365	18	AAW35131	R. pipiens recombi
38	510	87.6	107	18	AAW35120	R. pipiens recombi
39	477	82.0	107	18	AAW35128	R. pipiens recombi
40	465.5	80.0	111	18	AAW35121	R. pipiens recombi
41	427	73.4	83	18	AAW35119	R. pipiens clone R
42	427	73.4	83	20	AAW88234	Rana pipiens RNase
43	274	47.1	111	20	AAW33321	Frog lectin protei
44	272.5	46.8	111	20	AAW28876	Recombinant Met(-1
45	271.5	46.6	111	20	AAV28873	Recombinant Met(-1

ALIGNMENTS

RESULT 1	AAV28869	standard: Protein; 105 AA.
ID	AAV28869	
XX	AAV28869:	
AC	25-JAN-2000	(first entry)
XX	Recombinant Met(-1)	RAPLRI Met23Leu-(His)6 protein.
DE	XX	
XX	Recombinant Met(-1)	Rana pipiens ribonuclease Met23Leu-(His)6: RAPLRI:
KW	CD22: covalently bound; H12 antibody; ligand binding motif; RNase;	
KW	cancerous B cell; Kapos's sarcoma; human chorionic gonadotropin; HCG;	
KW	signal peptide; recombinant ribonuclease; cytotoxic fusion protein;	
KW	cancer; frog; autoimmune disease.	
XX	XX	
XX	Rana pipiens.	
OS	Synthetic.	
XX	XX	
FT	Key	Location/Qualifiers
FT	Misc-difference 1	/note- "(His)6 histidine tag attached to N-terminal Met"
FT	Misc-difference 1	
FT	Misc-difference 1	
FT	Misc-difference 24	/note- "Met not found in wild type RAPLRI"
FT	Misc-difference 24	/note- "wild type Met replaced with Leu"
PD	W09950398-A2.	
XX	07-OCT-1999.	
XX	26-MAR-1999:	99WD-US06641.
XX	XX	

```

PR 27-MAR-1998; 98US-0079751.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Newton DL, Rybak SM;
XX
DR WPI; 1999-610847/52.
XX
DR N-PSDB; AA208126.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases
XX
PS Claim 4; Page 59; 71pp; English.
XX
XX The present sequence is a recombinant Rana pipiens ribonuclease protein
CC (RapLRI) with Met at position 1 attached to (His)6 tag and Met24Leu
CC Carboxy terminal end of recombinant RapLRI has a covalently bound ligand
CC binding moiety, which can be a LL2 antibody directed against CD22 on
CC cancerous B cells or human chorionic gonadotropin (hCG) effective
CC against Kaposi's sarcoma cells. Recombinant ribonucleases can be
CC expressed in bacteria without an N-terminal methionine due to the
CC presence of a signal peptide that is cleaved by bacteria. The soluble
CC expression of ribonuclease allows the proteins to be fused in-frame with
CC ligand binding moieties to form cytotoxic fusion proteins. They can be
CC used for treatment of cancer and autoimmune diseases.
XX
SQ Sequence 105 AA:
XX
Query Match 97.4%; Score 567; DB 20; Length 105;
Best Local Similarity 98.1%; Pred. No. 1.3e-60;
Matches 103; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 MODWLTFQKKHLNTRDVCNNILSTNLFHCCKDNFTFYSRPPVKAICKGIISKNVLT 60
DB 1 MODWLTFQKKHLNTRDVCNNILSTNLFHCCKDNFTFYSRPPVKAICKGIISKNVLT 60
QY 61 TFEFYISDCNVTSRPPCKYKLLKSTITFCVTCENQAPVHFVGHC 105
DB 61 TSEFYISDCNVTSRPPCKYKLLKSTITFCVTCENQAPVHFVGHC 105

RESULT 2
AAV28867
ID AAV28867 standard; Protein: 105 AA.
XX
AC AAV28867;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant Met(-1) RapLRI.
XX
KW Recombinant Met(-1) Rana pipiens ribonuclease; RapLRI; CD22; RNase;
KW covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW Kaposi's sarcoma; human chorionic gonadotropin; hCG; signal peptide;
KW recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW autoimmune disease.
XX
OS Rana pipiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX FT Misc-difference 1 /note- "Met not found in wild type RapLRI"
XX
XX WO950398-A2.
XX
XX PD 07-OCT-1999.
XX
XX PF 26-MAR-1999; 99WO-US06641.
XX
XX PR 27-MAR-1998; 98US-0079751.
XX
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX

```

```

XX
PI Newton DL, Rybak SM;
XX
DR WPI; 1999-610847/52.
XX
DR N-PSDB; AA208126.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases
XX
PS Claim 34; Page 57; 71pp; English.
XX
XX The present sequence is a recombinant Rana pipiens ribonuclease (RapLRI)
CC protein with Met at position 1. Carboxy terminal end of recombinant
CC RapLRI has a covalently bound ligand binding moiety, which can be a LL2
CC antibody directed against CD22 on cancerous B cells or human chorionic
CC gonadotropin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC ribonucleases can be expressed in bacteria without an N-terminal
CC methionine due to the presence of a signal peptide that is cleaved by
CC bacteria. The soluble expression of ribonuclease allows the proteins to
CC be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC proteins. They can be used for treatment of cancer and autoimmune
CC diseases.
XX
SQ Sequence 105 AA:
XX
Query Match 97.1%; Score 565; DB 20; Length 105;
Best Local Similarity 97.1%; Pred. No. 2.2e-60;
Matches 102; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MODWLTFQKKHLNTRDVCNNILSTNLFHCCKDNFTFYSRPPVKAICKGIISKNVLT 60
DB 1 MODWLTFQKKHLNTRDVCNNILSTNLFHCCKDNFTFYSRPPVKAICKGIISKNVLT 60
QY 61 TFEFYISDCNVTSRPPCKYKLLKSTITFCVTCENQAPVHFVGHC 105
DB 61 TSEFYISDCNVTSRPPCKYKLLKSTITFCVTCENQAPVHFVGHC 105

RESULT 3
AAV28866
ID AAV28866 standard; Protein: 104 AA.
XX
AC AAV28866;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant RapLRI Met23Leu amino acid sequence.
XX
KW Recombinant Rana pipiens ribonuclease; RapLRI Met23Leu; covalently bound;
KW LL2 antibody; ligand binding moiety; CD22; cancerous B cell; RNase;
KW Kaposi's sarcoma; human chorionic gonadotropin; hCG; signal peptide;
KW recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW autoimmune disease.
XX
OS Rana pipiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX FT Misc-difference 23 /note- "Wild type Met replaced with Leu"
XX
XX WO950398-A2.
XX
XX PD 07-OCT-1999.
XX
XX PF 26-MAR-1999; 99WO-US06641.
XX
XX PR 27-MAR-1998; 98US-0079751.
XX
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX PI Newton DL, Rybak SM;
XX

```

DR WPI: 1999-610847/52.
DR N-PSDB: AA208125.
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases
XX
XX
PS Claim 34; Page 56; 71pp; English.
XX
CC The present sequence is a recombinant Rana pipiens ribonuclease (RapLr1)
CC protein with Met23leu. Carboxy terminal end of recombinant RapLr1 has a
CC covalently bound ligand binding moiety, which can be a LL2 antibody
CC directed against CD22 on cancerous B cells or human chorionic
CC gonadotrophin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC methionine due to the presence of a signal peptide that is cleaved by
CC bacteria. The soluble expression of ribonuclease allows the proteins to
CC be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC proteins. They can be used for treatment of cancer and autoimmune
CC diseases.
XX
SQ Sequence 104 AA:
Query Match 96.6%; Score 562; DB 20; Length 104;
Best Local Similarity 98.1%; Pred. No. 5.1e-60;
Matches 102; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2 ODMITFOKKHLTNRDVDCNNILSTNLFHCKDKNTFTYSRPEPKAICKGIIASKNVLT 61
DB 1 ODMITFOKKHLTNRDVDCNNILSTNLFHCKDKNTFTYSRPEPKAICKGIIASKNVLT 60
OY 62 FEFTLSDCNVTSRPCCKYKIKKSTTFCVTCENQAPVHFVGVGHC 105
DB 61 SEFTLSDCNVTSRPCCKYKIKKSTTFCVTCENQAPVHFVGVGHC 104
RESULT 4
AA28865
ID AAY28865 standard; Protein: 104 AA.
XX
AC AAY28865:
XX
DT 25-JAN-2000 (first entry)
XX
DE Rana pipiens: liver ribonuclease (RapLr1).
XX
KW Rana pipiens: liver ribonuclease; RapLr1; covalently bound; LL2 antibody;
KW ligand binding moiety; CD22; cancerous B cell; Kaposi's Sarcoma; frog;
KW human chorionic gonadotrophin; hCG; recombinant ribonuclease; RNase;
KW signal peptide; cytotoxic fusion protein; cancer; autoimmune disease.
XX
OS Rana pipiens:
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX
PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Newton DL, Rybak SM;
XX
DR WPI: 1999-610847/52.
DR N-PSDB: AA208124.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases
XX
PS Claim 1; Page 55; 71pp; English.
XX
CC The present sequence is Rana pipiens liver ribonuclease (RapLr1)

CC protein. Carboxy terminal end of RapLr1 has a covalently bound
CC ligand binding moiety, which can be a LL2 antibody directed against
CC CD22 on cancerous B cells or human chorionic gonadotrophin (hCG)
CC effective against Kaposi's Sarcoma cells. Recombinant ribonucleases can
CC be expressed in bacteria without an N-terminal methionine due to the
CC presence of a signal peptide that is cleaved by bacteria. The soluble
CC expression of ribonuclease allows the proteins to be fused in-frame with
CC ligand binding moieties to form cytotoxic fusion proteins. They can be
CC used for treatment of cancer and autoimmune diseases.
XX
SQ Sequence 104 AA:
Query Match 96.2%; Score 560; DB 20; Length 104;
Best Local Similarity 97.1%; Pred. No. 8.8e-60;
Matches 101; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY 2 ODMITFOKKHLTNRDVDCNNILSTNLFHCKDKNTFTYSRPEPKAICKGIIASKNVLT 61
DB 1 ODMITFOKKHLTNRDVDCNNIMSTNLFHCKDKNTFTYSRPEPKAICKGIIASKNVLT 60
OY 62 FEFTLSDCNVTSRPCCKYKIKKSTTFCVTCENQAPVHFVGVGHC 105
DB 61 SEFTLSDCNVTSRPCCKYKIKKSTTFCVTCENQAPVHFVGVGHC 104
RESULT 5
AA28871
ID AAY28871 standard; Protein: 105 AA.
XX
AC AAY28871:
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant Met(-1) RapLr1 GlnSer amino acid sequence.
XX
KW Recombinant Met(-1) Rana pipiens ribonuclease GlnSer; RapLr1; CD22;
KW covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW autoimmune disease; RNase.
XX
OS Rana pipiens.
XX
OS Synthetic.
XX
FH Key location/Qualifiers
FT Misc-difference 1 /note= "Met not found in wild type RapLr1"
FT Misc-difference 2 /note= "wild type Gln replaced with Ser"
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX
PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Newton DL, Rybak SM;
XX
DR WPI: 1999-610847/52.
DR N-PSDB: AA208129.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases
XX
PS Claim 34; Page 61; 71pp; English.
XX
CC The present sequence is a recombinant Rana pipiens ribonuclease (RapLr1)
CC protein with Met at position 1 and GlnSer. Carboxy terminal end of
CC recombinant RapLr1 has a covalently bound ligand binding moiety, which

CC ribonucleases can be expressed in bacteria without an N-terminal methionine due to the presence of a signal peptide that is cleaved by bacteria. The soluble expression of ribonuclease allows the proteins to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. They can be used for treatment of cancer and autoimmune diseases.

XX Sequence 104 AA;

Query Match 95.4%; Score 555; DB 20; Length 104;
Best Local Similarity 97.1%; Pred. No. 3.5e-59;
Matches 100; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 3 DMILTFQKKHLITNTRDVCNNITLSTNLFHCKDKNTFYISRPPEVKAICKGIASKNVLTF 62
DB 2 DMILTFQKKHLITNTRDVCNNITLSTNLFHCKDKNTFYISRPPEVKAICKGIASKNVLTF 61

OY 63 EFYLSDCNVTSRPCKYKRLKSTITFCVTCENQAPVHFVGVGHC 105
DB 62 EFYLSDCNVTSRPCKYKRLKSTITFCVTCENQAPVHFVGVGHC 104

RESULT 8
ID AAM06544 standard; Protein: 104 AA.

XX AAM06544;

XX 22-AUG-1997 (first entry)

XX Antitumour protein from Rana pipiens oocytes.

XX Tumour; chemotherapy; radiotherapy; frog.

XX Rana pipiens.

XX W09639428-A1.

XX 12-DEC-1996.

XX 03-JUN-1996; 96WO-US08304.

XX 06-JUN-1995; 95US-0467955.

XX (ALFA-) ALFACELL CORP.

XX Ardelt WJ;

XX WPI: 1997-043063/04.

XX Antitumour proteins from Rana pipiens oocyte(s) - have fewer disadvantages than chemotherapy, surgery and radiotherapy

XX Claim 8; Page 28; 45pp; English.

CC The present sequence is a specifically claimed example of an antitumour protein from the generic protein in AAM189224, with the molecular weight 12000. This is one of two preferred proteins (the other in AAM06543) that have been isolated from Rana pipiens oocytes. Both proteins have a blocked amino terminal group and are essentially free of carbohydrates. The proteins are used to treat tumours. Use of the peptides has fewer disadvantages than chemotherapy, radiotherapy and surgery in the treatment of tumours.

XX Sequence 104 AA;

Query Match 92.8%; Score 540; DB 18; Length 104;
Best Local Similarity 93.3%; Pred. No. 2.3e-57;
Matches 97; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

OY 2 DMILTFQKKHLITNTRDVCNNITLSTNLFHCKDKNTFYISRPPEVKAICKGIASKNVLTF 61
DB 1 EFWLTFQKKHLITNTRDVCNNITLSTNLFHCKDKNTFYISRPPEVKAICKGIASKNVLTF 60

OY 62 EFYLSDCNVTSRPCKYKRLKSTITFCVTCENQAPVHFVGVGHC 105
DB 61 EFYLSDCNVTSRPCKYKRLKSTITFCVTCENQAPVHFVGVGHC 104

RESULT 9
ID AAM35123 standard; Protein: 105 AA.

XX AAM35123;

XX 20-APR-1998 (first entry)

XX R. pipiens recombinant RNase protein [Met-(1)]ironc.

XX RNase A; ribonuclease; cytotoxic; onconase; nonc; immunofusion;

XX tumour cell growth; frog.

XX Rana pipiens.

XX W09731116-A2.

XX 28-AUG-1997.

XX 19-FEB-1997; 97WO-US02588.

XX 21-FEB-1996; 96US-0011800.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Bogue L, Newton DL, Rybak SM, Wlodawer A;

XX WPI: 1997-435168/40.

XX N-PSDB: AAT94959.

XX Ribonuclease molecules based on native Onconase - used for killing cells, particularly tumour cells

XX Disclosure: Pages 65-66; 90pp; English.

CC AAM35115 to AAM35123 encode recombinant proteins (rONC) which are modifications of the RNase Onconase (rONC). Such novel ribonuclease molecules are highly cytotoxic and can be used alone or to form chemical conjugates or to target recombinant immunofusions. They are used particularly for decreasing tumour cell growth. They can also be used for cell separation in vitro by selectively killing unwanted types of cells, e.g. in bone marrow prior to transplantation into a patient undergoing marrow ablation by radiation, or for killing leukaemia cells or T-cells that would cause graft versus host disease. The toxins can also be used to selectively kill unwanted cells in culture. The new ribonucleases have increased cytotoxic activity compared to nonc and also lower immunogenicity in humans.

XX Sequence 105 AA;

Query Match 92.8%; Score 540; DB 18; Length 105;
Best Local Similarity 92.4%; Pred. No. 2.3e-57;
Matches 97; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

OY 1 MODMLTFQKKHLITNTRDVCNNITLSTNLFHCKDKNTFYISRPPEVKAICKGIASKNVLTF 60
DB 1 MEDMLTFQKKHLITNTRDVCNNITLSTNLFHCKDKNTFYISRPPEVKAICKGIASKNVLTF 60

OY 61 TFEYLSDCNVTSRPCKYKRLKSTITFCVTCENQAPVHFVGVGHC 105
DB 61 TFEYLSDCNVTSRPCKYKRLKSTITFCVTCENQAPVHFVGVGHC 105

RESULT 10
ID AAY39400 standard; Protein: 105 AA.

XX

OS Synthetic.
XX MO9731116-A2.
PN 28-AUG-1997.
XX 19-FEB-1997; 97MO-US02588.
XX 21-FEB-1996; 96US-0011800.
XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
PA Boque L, Newton DL, Rybak SM, Wlodawer A;
XX WPI: 1997-435168/4C.
DR N-PSDB; AAT94968.
XX Ribonuclease molecules based on native Onconase - used for killing
PT cells, particularly tumour cells
PS Disclosure; Page 72; 90pp; English.
XX Sequences AAM35125 to AAM35135 represent recombinant fusion proteins
CC (f0nc) which are modifications of the RNase Onconase (RTM) (f0nc). Such
CC novel ribonuclease molecules are highly cytotoxic and can be used alone
CC or to form chemical conjugates or to target recombinant immunofusions.
CC They are used particularly for decreasing tumour cell growth. They can
CC also be used for cell separation in vitro by selectively killing unwanted
CC types of cells; e.g. in bone marrow prior to transplantation into a
CC patient undergoing marrow ablation by radiation, or for killing leukaemia
CC cells or T-cells that would cause graft versus host disease. The toxins
CC can also be used to selectively kill unwanted cells in culture. The new
CC ribonucleases have increased cytotoxic activity compared to f0nc and
XX also lower immunogenicity in humans.
SQ Sequence 356 AA;
Query Match 92.8%; Score 540; DB 18; Length 358;
Best Local Similarity 92.4%; Pred. No. 1.1e-56;
Matches 97; Conservative 4; Mismatches 4; Indels 0; Gaps 0;
QY 1 MODWLTFOKKHILNTNRDVCNNILSTNLFHCKDKNTFYSRPEPVKAICGIIASKNVLT 60
DB 1 MEWMLTFQKKHINTNRDVCNNILSTNLFHCKDKNTFYSRPEPVKAICGIIASKNVLT 60
QY 61 TFEYLSDCNVTSRPCKYKLLKSTTFECVTCENQAPVHFVGSHC 105
DB 61 TSEYLSDCNVTSRPCKYKLLKSTTFECVTCENQAPVHFVGSC 105
RESULT 13
AAM30301
ID AAM30301 standard; protein: 104 AA.
XX AAM30301;
AC 09-JUN-1998 (first entry)
DT Recombinant onc protein.
XX
DE
XX
KW Onc; onconase; ribonuclease; frog; antitumour; pancreatic cancer;
KM human immunodeficiency virus type-1; HIV1; replication.
XX
OS Rana pipiens.
XX
PN WO9738112-A1.
XX 16-OCT-1997.
XX 04-APR-1997; 97WD-US05675.
XX 04-APR-1996; 96US-0626288.
XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
XX Ardelit W, Boix E, Vasandani VM, Wu YN, Youle RJ;
XX WPI: 1997-512725/47.
DR
XX
XX Recombinant Onc protein with glutamine residue at position 1
PT useful as antitumour and antiviral agent, also as cell culture
PT selection agent
PS Claim 1; Page 28; 35pp; English.
XX
XX This sequence represents a recombinant Onc protein comprising a 104 amino
CC acid sequence having Gln at position 1. Onc, a ribonuclease from Rana
CC pipiens oocytes, is known as an antitumour agent (e.g. for treating
CC pancreatic cancer) and inhibitor of human immunodeficiency virus type-1
CC replication. It can be used therapeutically or as a cell-culture
CC selection agent, e.g. to identify gene therapy compositions able to
CC inhibit tumour growth.
SQ Sequence 104 AA;
Query Match 92.4%; Score 538; DB 18; Length 104;
Best Local Similarity 93.3%; Pred. No. 4e-57;
Matches 97; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
QY 2 QDWLTFOKKHILNTNRDVCNNILSTNLFHCKDKNTFYSRPEPVKAICGIIASKNVLT 61
DB 1 QDWLTFOKKHILNTNRDVCNNILSTNLFHCKDKNTFYSRPEPVKAICGIIASKNVLT 60
QY 62 FEEYLSDCNVTSRPCKYKLLKSTTFECVTCENQAPVHFVGSHC 105
DB 61 SEFYLSDCNVTSRPCKYKLLKSTTFECVTCENQAPVHFVGSC 104
RESULT 14
AAB31666
ID AAB31666 standard; protein: 104 AA.
XX AAB31666;
AC 30-APR-2001 (first entry)
DT Amino acid sequence of a frog ribonuclease protein.
XX
DE
XX
KM Frog; ribonuclease; ranpirinase; RNase.
XX
OS Rana pipiens.
XX
XX Key Location/Qualifiers
FT Modified-site 1 /note="this Gln is autocyclised to pyroglutamic acid"
FT
XX US6175003-B1.
PN 16-JAN-2001.
XX
PD 10-SEP-1999; 99US-0394268.
XX
FE 10-SEP-1999; 99US-0394268.
XX
PR 10-SEP-1999; 99US-0394268.
XX
PA (ALFA-) ALFACELL CORP.
XX
PI Saxena SK;
XX
XX WPI: 2001-167808/17.
XX
XX New nucleic acids encoding a ribonuclease (Rnase), useful for the
PT precise targeting of Rnase to a predetermined cell receptor
XX
XX Claim 1; Columns 5-6; 7pp; English.
XX
XX The present sequence represents a frog ribonuclease protein (ranpirinase)
CC

